|
1
|
Chai GS, Duan DX, Ma RH, et al: Humanin
attenuates Alzheimer-like cognitive deficits and pathological
changes induced by amyloid β-peptide in rats. Neurosci Bull.
30:923–935. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang S and Jia J: Promoter polymorphisms
which modulate BACE1 expression are associated with sporadic
Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet.
153B:159–166. 2010.PubMed/NCBI
|
|
3
|
Pera M, Alcolea D, Sánchez-Valle R, et al:
Distinct patterns of APP processing in the CNS in
autosomal-dominant and sporadic Alzheimer disease. Acta
Neuropathol. 125:201–213. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tang J, Pei Y and Zhou G: When aging-onset
diabetes is coming across with Alzheimer disease: Comparable
pathogenesis and therapy. Exp Gerontol. 48:744–750. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yarchoan M and Arnold SE: Repurposing
diabetes drugs for brain insulin resistance in Alzheimer disease.
Diabetes. 63:2253–2261. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ghasemi R, Dargahi L, Haeri A, Moosavi M,
Mohamed Z and Ahmadiani A: Brain insulin dysregulation: Implication
for neurological and neuropsychiatric disorders. Mol Neurobiol.
47:1045–1065. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang T and Liu Y: Insulin resistance
animal model induced by high-energy dietary. Shi Yan Dong Wu Ke
Xue. 25:48–51. 2008.[(In Chinese)].
|
|
8
|
Bromley-Brits K, Deng Y and Song W: Morris
water maze test for learning and memory deficits in Alzheimer's
disease model mice. J Vis Exp. 53:29202011.PubMed/NCBI
|
|
9
|
Matsuzaki K: How do membranes initiate
Alzheimers Disease? Formation of toxic amyloid fibrils by the
amyloid β-protein on ganglioside clusters. Acc Chem Res.
47:2397–2404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Amaral AI, Teixeira AP, Håkonsen BI,
Sonnewald U and Alves PM: A comprehensive metabolic profile of
cultured astrocytes using isotopic transient metabolic flux
analysis and C-labeled glucose. Front Neuroenergetics. 3:52011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Charron MJ and Vuguin PM: Lack of glucagon
receptor signaling and its implications beyond glucose homeostasis.
J Endocrinol. 224:R123–R130. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Correia SC, Santos RX, Perry G, Zhu X,
Moreira PI and Smith MA: Insulin-resistant brain state: The culprit
in sporadic Alzheimer's disease? Ageing Res Rev. 10:264–273. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lannert H and Hoyer S:
Intracerebroventricular administration of streptozotocin causes
long-term diminutions in learning and memory abilities and in
cerebral energy metabolism in adult rats. Behav Neurosci.
112:1199–1208. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lesort M, Jope RS and Johnson GV: Insulin
transiently increases tau phosphorylation: Involvement of glycogen
synthase kinase-3β and Fyn tyrosine kinase. J Neurochem.
72:576–584. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jin Y, Fan Y, Yan EZ, Liu Z, Zong ZH and
Qi ZM: Effects of sodium ferulate on amyloid-β-induced
MKK3/MKK6-p38 MAPK-Hsp27 signal pathway and apoptosis in rat
hippocampus. Acta Pharmacol Sin. 27:1309–1316. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kondo M, Tokuda T, Itsukage M, et al:
distribution of amyloid burden differs between idiopathic normal
pressure hydrocephalus and Alzheimer's disease. Neuroradiol J.
26:41–46. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chu J, Zhuo JM and Praticò D:
Transcriptional regulation of β-secretase-1 by 12/15-lipoxygenase
results in enhanced amyloidogenesis and cognitive impairments. Ann
Neurol. 71:57–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chiocco MJ and Lamb BT: Spatial and
temporal control of age-related APP processing in genomic-based
β-secretase transgenic mice. Neurobiol Aging. 28:75–84. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vassar R: BACE1 inhibitor drugs in
clinical trials for Alzheimers disease. Alzheimers Res Ther.
6:892014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sonkusare S, Srinivasan K, Kaul C and
Ramarao P: Effect of donepezil and lercanidipine on memory
impairment induced by intracerebroventricular streptozotocin in
rats. Life Sci. 77:1–14. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
de la Monte SM, Tong M, Lester-Coll N,
Plater M Jr and Wands JR: Therapeutic rescue of neurodegeneration
in experimental type 3 diabetes: Relevance to Alzheimer's disease.
J Alzheimers Dis. 10:89–109. 2006.PubMed/NCBI
|
|
22
|
Grünblatt E, Salkovic-Petrisic M,
Osmanovic J, Riederer P and Hoyer S: Brain insulin system
dysfunction in streptozotocin intracerebroventricularly treated
rats generates hyperphosphorylated tau protein. J Neurochem.
101:757–770. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chabrier MA, Blurton-Jones M, Agazaryan
AA, Nerhus JL, Martinez-Coria H and LaFerla FM: Soluble Aβ promotes
wild-type tau pathology in vivo. J Neurosci. 32:17345–17350. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vassar R: β-secretase, APP and Aβ in
Alzheimer's disease. Subcell Biochem. 38:79–103. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yan R and Vassar R: Targeting the β
secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol.
13:319–329. 2014. View Article : Google Scholar : PubMed/NCBI
|
